Contact Us

Yes. PTEN rescue experiments in BEAS-2B are well-suited for lung cancer initiation research: • Construct design: use a codon-modified PTEN sequence with a small C-terminal tag (FLAG, HA). • Lung cancer initiation rescue: assessment of PTEN rescue-mediated reversal of transformation phenotypes (anchorage-independent growth, proliferation). • Cooperating mutation analyses: rescue with PTEN combined with oncogenic KRAS or EGFR expression for cooperativity studies. • Functional readout: rescue should suppress PI3K pathway hyperactivation and restore non-transformed bronchial epithelial growth characteristics. BEAS-2B transduces efficiently with lentivirus and supports stable rescue line generation in a non-tumorigenic lung epithelial background.

The choice depends on whether you are studying PSMB8 (LMP7, β5i)'s role as a catalytic subunit of the immunoproteasome or modeling proteasome-associated autoinflammatory syndromes (PRAAS, including CANDLE/Nakajo-Nishimura syndrome). The Knockout line is the standard tool for asking whether the immunoproteasome (where LMP7 replaces β5 of the standard proteasome) is required for these activities — immunoproteasome generates MHC class I peptides with improved hydrophobicity and altered cleavage specificity. Overexpression is useful for studying immunoproteasome assembly or for testing reconstitution with mutant subunits. For immunoproteasome research, the EDITGENE PSMB8 Knockout in HAP1 is highly informative — particularly when combined with the parallel PSMB10 Knockout (also available) for comprehensive immunoproteasome characterization. PRAAS-associated PSMB8 mutations enable disease genotype-function studies. Rescue with wild-type or catalytically-dead LMP7 is the standard specificity control. The knockout is a critical specificity tool for immunoproteasome-selective inhibitors (KZR-616/zetomipzomib, ONX-0914) in autoimmune disease drug development.

Yes. LMP7 rescue experiments require attention to proteasome assembly: • Construct design: use a codon-modified PSMB8 sequence with a small C-terminal tag (FLAG, HA, but very small tags preferred — proteasome subunit incorporation is sensitive to tag size). LMP7 is incorporated as a precursor that undergoes autocatalytic activation. • Catalytically-dead rescue: the T1A mutation in the active site threonine abolishes chymotrypsin-like activity and is the standard specificity control. • PRAAS mutation rescue: patient-derived PSMB8 mutations enable disease genotype-function correlation studies. • Functional readout: rescue should restore immunoproteasome assembly, chymotrypsin-like activity (LLE-AMC fluorogenic substrate), and IFN-γ-induced immunoproteasome formation. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying PTPN1 (PTP1B)'s role as the principal negative regulator of insulin and leptin receptor signaling or its emerging functions in cancer biology and airway epithelial signaling. The Knockout line is the standard tool for asking whether PTP1B is required for dephosphorylating IR, IRS-1/2, JAK2, and other RTK substrates — PTP1B is a major therapeutic target for type 2 diabetes and obesity. Overexpression is useful for studying PTP1B's reported tumor-promoting effects in some cancer contexts. For airway epithelial signaling research, the EDITGENE PTP1B Knockout in BEAS-2B is highly relevant — BEAS-2B is a non-tumorigenic human bronchial epithelial cell line, and PTP1B regulates EGFR and other respiratory epithelial RTK signaling. Rescue with wild-type or catalytically-dead (C215S) PTP1B is the standard specificity control. The knockout serves as a critical specificity tool for PTP1B inhibitors (trodusquemine/MSI-1436, JTT-551) in metabolic disease therapeutic development.

Yes. PTP1B rescue experiments are well-established for tyrosine phosphatase research: • Construct design: use a codon-modified PTPN1 sequence with a small C-terminal tag (FLAG, HA). PTP1B has N-terminal catalytic phosphatase domain and C-terminal ER-anchoring tail — preserve both elements. • Catalytically-dead rescue: the C215S mutation in the active site cysteine abolishes phosphatase activity and is the standard specificity control. • Substrate-trap rescue: D181A (substrate-trap mutant) generates a catalytically inactive form that retains substrate binding — invaluable for identifying PTP1B substrates by mass spectrometry. • Functional readout: rescue should restore IR, IRS-1, EGFR, and STAT3 dephosphorylation patterns. BEAS-2B is a non-tumorigenic bronchial epithelial cell line — transduction with lentivirus is supported and standard rescue protocols apply.

The choice depends on whether you are studying Meis1 (myeloid ecotropic viral integration site 1)'s role as a TALE-family homeodomain transcription factor or modeling its functions in hematopoietic stem cell maintenance, leukemogenesis, or restless legs syndrome. The Knockout line is the standard tool for asking whether Meis1 is required for these processes — Meis1 dimerizes with PBX family TALE transcription factors and HOX cofactors to drive transcription of HSC self-renewal programs; Meis1 is a HOXA9 cofactor in AML pathogenesis. Overexpression is useful for studying Meis1 in leukemic transformation contexts. Important consideration: Meis1 is principally functional in hematopoietic and embryonic tissue contexts — TM4 (immortalized murine Sertoli cells) is not the physiological context for canonical Meis1 functions. The EDITGENE Meis1 Knockout in TM4 is most useful for biochemistry, heterologous expression studies, and as a clean genetic background for Meis1 structure-function research. Meis1 polymorphisms are the strongest genetic risk factor for restless legs syndrome (RLS) — disease variant rescue enables genotype-function studies. Rescue with wild-type or DNA-binding-deficient Meis1 is the standard specificity control.

Yes. Meis1 rescue experiments require attention to TALE-family architecture: • Construct design: use a codon-modified Meis1 sequence with a small C-terminal tag (FLAG, HA). Meis1 has N-terminal MEIS-A/MEIS-B PBX-interaction domains, TALE homeodomain (DNA binding), and C-terminal transactivation region — preserve all elements. • DNA-binding-deficient rescue: homeodomain mutations disrupt DNA binding and serve as the standard specificity control. • PBX-interaction-deficient rescue: MEIS-A domain mutations disrupt PBX dimerization, enabling separation of DNA binding from cofactor partnership. • Functional readout: rescue should restore PBX-HOX-MEIS target gene expression in heterologous contexts. TM4-specific considerations: • TM4 is an immortalized immature murine (BALB/c) Sertoli cell line — the principal continuous Sertoli cell model retaining FSH responsiveness and key Sertoli cell features. • Lentiviral transduction is supported but may require optimization; primary Sertoli cell-specific features may be reduced compared to primary cultures. • TM4 has a non-diploid karyotype with multiple marker chromosomes — characterize transgene integration sites and expression levels carefully.

The choice depends on whether you are studying PMS1's role as the minor MutLβ partner of MLH1 or its less-characterized functions distinct from PMS2 (MutLα). The Knockout line is appropriate for asking whether PMS1 is required for these activities — PMS1 partners with MLH1 to form MutLβ, which is much less abundant than MutLα and whose contribution to mismatch repair has been controversial; recent studies suggest specialized functions in certain repair contexts. Overexpression is useful for studying PMS1-specific functions in heterologous expression contexts. Important consideration: despite the gene name similarity, PMS1 contributes substantially less to mismatch repair than PMS2 — single PMS1 knockout typically shows modest MMR phenotypes. PMS1 was historically considered a Lynch syndrome gene but is no longer classified as such by major consensus criteria. Rescue with wild-type PMS1 is the standard specificity control. The knockout is valuable for characterizing the specialized roles of MutLβ in DNA repair distinct from MutLα.

Yes. PMS1 rescue experiments require attention to MLH1 partnership: • Construct design: use a codon-modified PMS1 sequence with a small C-terminal tag (FLAG, HA). PMS1 has the canonical MutL family architecture with N-terminal ATPase domain and C-terminal MLH1-interaction region — preserve both. • MLH1 partnership: PMS1 requires MLH1 for MutLβ formation — rescue interpretation should consider MLH1 expression and MutLα versus MutLβ competition. • Discovery-oriented rescue: parallel wild-type rescue helps distinguish PMS1-dependent phenotypes given its specialized rather than canonical MMR role. • Functional readout: rescue should restore MutLβ-specific repair activities; classical MMR readouts may be less informative than for PMS2 rescue. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying MTCH2 (mitochondrial carrier homolog 2)'s role as a mitochondrial outer membrane protein insertase or its functions in mitochondrial biology and apoptosis. The Knockout line is the standard tool for asking whether MTCH2 is required for these processes — MTCH2 was recently characterized as a major mitochondrial outer membrane (MOM) protein insertase (a 'mitochondrial translocase'), inserting α-helical MOM proteins into the lipid bilayer; this is in addition to MTCH2's longer-known roles in tBID-induced apoptosis and adipocyte differentiation. Overexpression is useful for studying MTCH2 in heterologous contexts. For mitochondrial biology research, the EDITGENE MTCH2 Knockout in HEK293 is highly informative — the recent discovery that MTCH2 acts as a major MOM protein insertase represents a paradigm shift in understanding mitochondrial protein import. Rescue with wild-type or insertase-deficient MTCH2 enables structure-function studies of this newly characterized translocase activity. The knockout is valuable for studying mitochondrial proteome biogenesis, apoptosis regulation (tBID-MTCH2 interaction releases cytochrome c), and adipocyte biology (MTCH2 has been characterized in adipogenesis).

Yes. MTCH2 rescue experiments require attention to mitochondrial outer membrane targeting: • Construct design: use a codon-modified MTCH2 sequence with a small C-terminal tag (FLAG, HA). MTCH2 has the mitochondrial carrier family architecture (six transmembrane domains) — preserve topology for proper MOM insertion. • Insertase-deficient rescue: structure-function mutations affecting the recently characterized MOM protein insertase activity enable separation of insertase from other MTCH2 functions. • tBID-binding-deficient rescue: specific mutations affecting tBID interaction enable separating apoptosis-related from translocase functions. • Functional readout: rescue should restore mitochondrial proteome composition, tBID-induced MOMP, and apoptosis responses. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying PMS2's role as the dominant MutLα partner of MLH1 in mismatch repair or modeling Lynch syndrome and constitutional mismatch repair deficiency (CMMRD) syndrome. The Knockout line is the standard tool for asking whether PMS2 is required for mismatch repair — PMS2 partners with MLH1 to form MutLα, the principal MutL-family complex in human MMR, providing endonuclease activity that introduces strand-specific nicks during repair. Overexpression is useful for studying PMS2 in heterologous expression contexts or for testing disease-associated mutations. For mismatch repair research, the EDITGENE PMS2 Knockout in HEK293 is a workhorse mechanistic platform — HEK293 has been extensively used for MMR biochemistry and structure-function studies. PMS2 mutations cause Lynch syndrome (HNPCC) and, when biallelic, constitutional mismatch repair deficiency (CMMRD) — disease variant rescue enables genotype-function studies. Rescue with wild-type or endonuclease-dead (E705K) PMS2 enables comprehensive structure-function studies. The knockout is valuable for studying PMS2-deficient cancer immunotherapy response — MMR-deficient tumors have high mutation burden and increased sensitivity to immune checkpoint inhibitors.

Yes. PMS2 rescue experiments are well-established for MMR research: • Construct design: use a codon-modified PMS2 sequence with a small C-terminal tag (FLAG, HA). PMS2 has N-terminal ATPase domain, central CTH-binding region, and C-terminal endonuclease domain (DQHA-X(2)-E-X(4)-E motif) — preserve all elements. • Endonuclease-dead rescue: the E705K mutation in the conserved endonuclease motif abolishes nicking activity and is the standard specificity control. • MLH1 interaction: rescue interpretation considers MLH1 expression — PMS2 requires MLH1 for stability and MutLα formation. • Disease mutation rescue: Lynch/CMMRD-associated PMS2 mutations enable comprehensive disease genotype-function studies. • Functional readout: rescue should restore MMR activity (in vitro reconstitution), microsatellite stability, and 6-thioguanine sensitivity. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying PEBP1 (RKIP, Raf kinase inhibitor protein)'s role as a metastasis suppressor or its functions inhibiting Raf-MEK-ERK signaling and IKK/NF-κB pathways. The Knockout line is the standard tool for asking whether RKIP is required for these inhibitory functions — RKIP binds and inhibits Raf-1, MEK1, GRK2, and IKK, broadly attenuating proliferative and inflammatory signaling. Overexpression is useful for studying RKIP tumor suppressor functions in cancer contexts. For cancer biology research, the EDITGENE PEBP1 Knockout in HEK293 enables study of Raf-MEK-ERK and NF-κB pathway hyperactivation following RKIP loss. Rescue with wild-type or phospho-RKIP-mimetic (S153D, which switches RKIP from Raf inhibition to GRK2 inhibition) enables comprehensive structure-function studies. RKIP loss is associated with metastatic progression in multiple cancers — the knockout serves as a tool for studying metastasis-permissive signaling networks.

Yes. RKIP rescue experiments are well-established for signaling research: • Construct design: use a codon-modified PEBP1 sequence with a small C- or N-terminal tag (FLAG, HA). RKIP is small (~21 kDa) cytoplasmic protein — both tag positions are typically tolerated. • Raf-binding-deficient rescue: specific residue mutations in the Raf-binding interface enable separating Raf inhibition from GRK2 inhibition. • Phospho-mimetic rescue: S153D mutation mimics PKC-phosphorylated RKIP, switching from Raf to GRK2 inhibition — invaluable for studying RKIP's dual regulation. • Functional readout: rescue should restore Raf-MEK-ERK pathway attenuation, NF-κB pathway inhibition, and metastasis suppressor phenotypes. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.